Aprea Therapeutics, Inc.

Aprea Therapeutics is a clinical-stage precision medicine biopharmaceutical company dedicated to discovering and developing targeted therapies for patients with biomarker-defined cancers. Utilizing the concept of synthetic lethality, the company designs small molecule inhibitors that target specific cancer-related genetic alterations and DNA damage response pathways to selectively destroy cancer cells while sparing healthy tissue. Aprea Therapeutics focuses on advancing its core pipeline programs, which feature its clinical-stage WEE1 kinase inhibitor, APR-1051, and its oral macrocyclic ATR inhibitor, ATRN-119, alongside preclinical candidates such as the DYRK1 inhibitor APR-1602.

The company operates primarily through research, clinical development, and translational collaborations in the United States, conducting active clinical trials across multiple study sites nationwide. Aprea Therapeutics relies on third-party contract manufacturers for the synthesis of active pharmaceutical ingredients and clinical trial drug supplies. The provided text notes that Aprea Therapeutics AB originally incorporated in 2002 before a corporate reorganization established Aprea Therapeutics, Inc. as the parent entity, but does not disclose specific headquarters facilities or locations.

Summary of the business section of Aprea Therapeutics's latest annual report, written by StockData.

“As of December 31, 2025, we had 8 full-time employees, of which 5 employees are directly engaged in research and development with the rest providing administrative, business and operations support.”